News | August 10, 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
EDQM has also issued a Certificate of Suitability for Allopurino
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
